Curis Lifesciences Limited
NNSE:CURIS185.00
INR
0.00
(0.00%)
ISIN
INE1BZN01016
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Dharmesh D. Patel
- Full Time Employees
- 80
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ahmedabad India
- IPO Date
- Nov 14, 2025
- Website
- curisls.com
- Similar Companies
- Business
- Curis Lifesciences Limited is an India-based pharmaceutical company engaged in the research, development, manufacturing, marketing, and contract manufacturing of a wide range of pharmaceutical formulations, nutraceuticals, and wellness products. Founded in 2010 and headquartered in Ahmedabad, Gujarat, India, the company operates as both a commercial pharmaceutical provider and a contract development and manufacturing organization (CDMO), serving institutional healthcare clients, retail distribution channels, and third-party brand owners across domestic and international markets. The company's core product portfolio encompasses diverse finished dosage forms and therapeutic categories, organized into: solid oral dosage forms, including immediate-release tablets, sustained-release tablets, dispersible tablets, effervescent tablets, and hard and soft gelatin capsules; liquid orals, including pharmaceutical syrups, oral suspensions, pediatric drops, and oral rehydration solutions; topical and dermatological formulations, including medicated creams, ointments, gels, lotions, and dusting powders; sterile parenteral preparations, including liquid injectable ampoules and dry powder injectables; and nutraceutical and dietary supplements, including multivitamin complexes, mineral formulations, antioxidant blends, effervescent nutritional tablets, and protein powders. Curis Lifesciences' therapeutic offerings span anti-infectives and antibiotics; gastrointestinal therapies, including antacids, proton pump inhibitors, and antiemetics; pain management and anti-inflammatory medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants; respiratory and anti-allergic medications, including antihistamines, bronchodilators, and cough syrups; cardiovascular and metabolic care products; and dermatological and skin treatment solutions. In addition to commercial product distribution, the company offers third-party contract manufacturing, formulation development, custom packaging, analytical testing, and regulatory documentation services. Curis Lifesciences Limited conducts business across domestic and global markets, maintaining a nationwide distribution network in India while exporting pharmaceutical formulations to emerging and semi-regulated markets across Southeast Asia, Africa, the Middle East, the Commonwealth of Independent States (CIS), and Latin America. Its manufacturing operations are conducted through modern, WHO-GMP compliant facilities equipped with automated production machinery, quality control laboratories, and packaging lines designed to meet international pharmaceutical manufacturing standards. In recent developments, Curis Lifesciences completed its corporate reorganization and conversion into a public limited entity, culminating in the listing of its equity shares on the National Stock Exchange of India (NSE: CURIS) to support manufacturing capacity expansion and strengthen working capital. Over the past two years, the company has executed strategic capacity enhancement and modernization initiatives across its formulation and packaging infrastructure to align with PIC/S and updated cGMP regulatory guidelines. Furthermore, Curis Lifesciences has expanded its CDMO and third-party manufacturing partnerships with prominent domestic healthcare companies, launched new specialty nutraceutical and therapeutic product lines, and broadened its international marketing alliances to expand its global distribution footprint.